Страна: САЩ
Език: английски
Източник: NLM (National Library of Medicine)
LOSARTAN POTASSIUM (UNII: 3ST302B24A) (LOSARTAN - UNII:JMS50MPO89)
MedVantx, Inc.
LOSARTAN POTASSIUM
LOSARTAN POTASSIUM 50 mg
ORAL
PRESCRIPTION DRUG
Losartan potassium tablets USP are indicated for the treatment of hypertension. Losartan potassium may be used alone or in combination with other antihypertensive agents, including diuretics. Losartan potassium tablets USP are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See PRECAUTIONS, Race and CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Reduction in the Risk of Stroke, Race.) Losartan potassium is contraindicated in patients who are hypersensitive to any component of this product.
Losartan Potassium Tablets USP are available as follows: 25 mg – Each white, round, biconvex film coated tablets debossed with ‘572’ on one side and the on the opposite side. Tablets are supplied in bottles of 30 (NDC 16714-581-01), 90 (NDC 16714-581-02), and 1000 (NDC 416714-581-03). 50 mg – Each white, round, biconvex film coated tablets debossed with ‘573’ on one side and the on the opposite side. Tablets are supplied in bottles of 30 (NDC 16714-582-01), 90 (NDC 16714-582-02), and 1000 (NDC 16714-582-03). 100mg – Each white, oval, biconvex film coated tablets debossed with ‘574’ on one side and the on the opposite side. Tablets are supplied in bottles of 30 (NDC 16714-583-01), 90 (NDC 16714-583-02), and 1000 (NDC 16714-583-03. Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Keep container tightly closed. Protect from light. Dispense in a tight, light-resistant container as defined in USP. Manufactured for: Northstar Rx LLC Memphis, TN 38141 Toll Free: 1-800-206-7821 Manufactured by: Actavis Pharma Manufacturing Pvt Ltd. Plot No. 101, 102, 107 & 108 SIDCO Pharmaceutical Complex Alathur, Kanchipuram Dist.-603 110 Tamilnadu, India. 50402649-00 Revised – February 2010
Abbreviated New Drug Application
LOSARTAN POTASSIUM- LOSARTAN POTASSIUM TABLET, FILM COATED MEDVANTX, INC. ---------- LOSARTAN POTASSIUM TABLETS USP 50402649-00 Revised – February 2010 RX ONLY USE IN PREGNANCY WHEN USED IN PREGNANCY DURING THE SECOND AND THIRD TRIMESTERS, DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE INJURY AND EVEN DEATH TO THE DEVELOPING FETUS. When pregnancy is detected, losartan potassium should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality. DESCRIPTION Losartan potassium USP is an angiotensin II receptor (type AT ) antagonist. Losartan potassium, a non- peptide molecule, is chemically described as 2-butyl-4-chloro-1-[_p_-(_o_-1_H _-tetrazol-5- ylphenyl)benzyl]imidazole-5-methanol monopotassium salt. Its empirical formula is C H ClKN O, and its structural formula is: Losartan potassium USP is a white to off-white free-flowing crystalline powder with a molecular weight of 461.00. It is freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents, such as acetonitrile and methyl ethyl ketone. Oxidation of the 5-hydroxymethyl group on the imidazole ring results in the active metabolite of losartan. Losartan potassium USP is available as tablets for oral administration containing either 25 mg, 50 mg or 100 mg of losartan potassium and the following inactive ingredients: croscarmellose sodium, hypromellose, magnesium stearate, mannitol, microcrystalline cellulose, povidone, propylene glycol, talc, titanium dioxide. Losartan potassium tablets USP 25 mg, 50 mg and 100 mg contain potassium in the following amounts: 2.12 mg (0.054 mEq), 4.24 mg (0.108 mEq) and 8.48 mg (0.216 mEq), respectively. Losartan potassium 25 mg, losartan potassium 50 mg, and losartan potassium 100 mg may also contain carnauba wax. 1 22 22 6 CLINICAL PHARMACOLOGY MECHANISM OF ACTION Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is a potent vasoconstrictor, the primary vasoactive hormone of Прочетете целия документ